Symbols / KZR $7.26 -0.41% Kezar Life Sciences, Inc.
KZR Chart
About
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Market Cap | 53.52M | Enterprise Value | -15.81M | Income | -56.03M | Sales | — | Book/sh | 9.56 | Cash/sh | 9.75 |
| Dividend Yield | — | Payout | 0.00% | Employees | 9 | IPO | — | P/E | — | Forward P/E | -2.72 |
| PEG | — | P/S | — | P/B | 0.76 | P/C | — | EV/EBITDA | 0.31 | EV/Sales | — |
| Quick Ratio | 11.23 | Current Ratio | 11.52 | Debt/Eq | 3.32 | LT Debt/Eq | — | EPS (ttm) | -7.66 | EPS next Y | -2.67 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-12 | ROA | -29.52% | ROE | -59.93% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 7.37M | Shs Float | 5.16M | Short Float | 2.79% |
| Short Ratio | 2.53 | Short Interest | — | 52W High | 7.55 | 52W Low | 3.53 | Beta | 0.43 | Avg Volume | 73.69K |
| Volume | 650.00 | Target Price | $6.00 | Recom | None | Prev Close | $7.29 | Price | $7.26 | Change | -0.41% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-17 | down | Jefferies | Buy → Hold | $7 |
| 2025-10-17 | down | William Blair | Outperform → Market Perform | — |
| 2025-10-17 | main | Wells Fargo | Equal-Weight → Equal-Weight | $5 |
| 2025-07-16 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-12-19 | main | Wells Fargo | Equal-Weight → Equal-Weight | $9 |
| 2024-12-02 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-11-14 | main | Wells Fargo | Equal-Weight → Equal-Weight | $11 |
| 2024-10-18 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-10-14 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-10-02 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2024-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-07-22 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-05-10 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-03-15 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2023-12-04 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2023-11-27 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2023-11-14 | main | Wells Fargo | Equal-Weight → Equal-Weight | $2 |
| 2023-10-12 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2023-10-05 | down | JonesTrading | Buy → Hold | — |
| 2023-09-25 | main | HC Wainwright & Co. | Buy → Buy | $20 |
News
RSS: Latest KZR news- Are KZR, TALK, WBD Obtaining Fair Deals for their Shareholders? - Stock Titan ue, 07 Apr 2026 07
- KZR Stock Alert: Halper Sadeh LLC is Investigating Whether Kezar Life Sciences, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire Mon, 30 Mar 2026 07
- Shareholder Alert: The Ademi Firm investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders - PR Newswire Mon, 30 Mar 2026 07
- Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat Fri, 10 Apr 2026 06
- Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive - Stocktwits Fri, 17 Oct 2025 17
- Kezar Life Sciences shares surge after Aurinia announces acquisition - MSN Mon, 30 Mar 2026 17
- Are KZR, NSA, EQH, CTRA Obtaining Fair Deals for their Shareholders? - Morningstar ue, 31 Mar 2026 07
- Kezar investors get cash now and future drug upside in Aurinia deal - Stock Titan Mon, 30 Mar 2026 07
- Are KZR, EQH, ULYX Obtaining Fair Deals for their Shareholders? - Morningstar ue, 14 Apr 2026 20
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR) - PR Newswire Mon, 30 Mar 2026 07
- Aurinia to buy Kezar (KZR) for $6.955/Share plus CVR (7.39M shares) - Stock Titan Mon, 13 Apr 2026 11
- Enodia pays up to $127M to deepen protein degradation research - Stock Titan hu, 12 Mar 2026 07
- Latest KZR News - Are KZR, TALK, WBD Obtaining Fair Deals for ... - Stock Titan hu, 16 Oct 2025 07
- Major Kezar (KZR) shareholder signs merger support pact and drops bid - Stock Titan Wed, 01 Apr 2026 07
- Baselake reports 5.3% stake in Kezar Life Sciences (NASDAQ: KZR) - Stock Titan Mon, 06 Apr 2026 07
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
-100.00%
|
7.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
-100.00%
|
7.00
|
0.00
|
| Operating Expense |
|
52.27
-41.36%
|
89.14
-20.58%
|
112.24
+57.72%
|
71.16
|
| Research And Development |
|
33.76
-48.65%
|
65.74
-23.29%
|
85.70
+68.00%
|
51.01
|
| Selling General And Administration |
|
18.51
-20.86%
|
23.39
-11.86%
|
26.54
+31.69%
|
20.15
|
| General And Administrative Expense |
|
18.51
-20.86%
|
23.39
-11.86%
|
26.54
+31.69%
|
20.15
|
| Other Gand A |
|
18.51
-20.86%
|
23.39
-11.86%
|
26.54
+31.69%
|
20.15
|
| Total Expenses |
|
52.27
-41.36%
|
89.14
-20.58%
|
112.24
+57.72%
|
71.16
|
| Operating Income |
|
-52.27
+41.36%
|
-89.14
+15.30%
|
-105.24
-47.88%
|
-71.16
|
| Total Operating Income As Reported |
|
-59.11
+34.76%
|
-90.61
+18.68%
|
-111.42
-56.58%
|
-71.16
|
| EBITDA |
|
-53.77
+33.71%
|
-81.10
+18.29%
|
-99.25
-50.31%
|
-66.03
|
| Normalized EBITDA |
|
-46.93
+41.07%
|
-79.63
+14.43%
|
-93.07
-40.94%
|
-66.03
|
| Reconciled Depreciation |
|
0.90
-13.75%
|
1.04
-2.44%
|
1.07
+4.20%
|
1.02
|
| EBIT |
|
-54.66
+33.45%
|
-82.14
+18.12%
|
-100.32
-49.61%
|
-67.05
|
| Total Unusual Items |
|
-6.84
-365.10%
|
-1.47
+76.24%
|
-6.19
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
-6.84
-365.10%
|
-1.47
+76.24%
|
-6.19
|
0.00
|
| Special Income Charges |
|
-6.84
-365.10%
|
-1.47
+76.24%
|
-6.19
|
0.00
|
| Restructuring And Mergern Acquisition |
|
5.74
+7367.09%
|
-0.08
-102.41%
|
3.28
|
0.00
|
| Write Off |
|
1.10
-29.24%
|
1.55
-46.73%
|
2.91
|
—
|
| Net Income |
|
-56.03
+33.08%
|
-83.74
+17.80%
|
-101.87
-49.28%
|
-68.24
|
| Pretax Income |
|
-56.03
+33.08%
|
-83.74
+17.80%
|
-101.87
-49.28%
|
-68.24
|
| Net Non Operating Interest Income Expense |
|
3.07
-55.25%
|
6.87
-28.10%
|
9.55
+226.86%
|
2.92
|
| Interest Expense Non Operating |
|
1.37
-14.00%
|
1.59
+2.77%
|
1.55
+30.80%
|
1.19
|
| Net Interest Income |
|
3.07
-55.25%
|
6.87
-28.10%
|
9.55
+226.86%
|
2.92
|
| Interest Expense |
|
1.37
-14.00%
|
1.59
+2.77%
|
1.55
+30.80%
|
1.19
|
| Interest Income Non Operating |
|
4.44
-47.48%
|
8.46
-23.79%
|
11.10
+170.30%
|
4.11
|
| Interest Income |
|
4.44
-47.48%
|
8.46
-23.79%
|
11.10
+170.30%
|
4.11
|
| Other Income Expense |
|
-6.84
-365.10%
|
-1.47
+76.24%
|
-6.19
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-56.03
+33.08%
|
-83.74
+17.80%
|
-101.87
-49.28%
|
-68.24
|
| Net Income From Continuing Operation Net Minority Interest |
|
-56.03
+33.08%
|
-83.74
+17.80%
|
-101.87
-49.28%
|
-68.24
|
| Net Income From Continuing And Discontinued Operation |
|
-56.03
+33.08%
|
-83.74
+17.80%
|
-101.87
-49.28%
|
-68.24
|
| Net Income Continuous Operations |
|
-56.03
+33.08%
|
-83.74
+17.80%
|
-101.87
-49.28%
|
-68.24
|
| Normalized Income |
|
-49.20
+40.20%
|
-82.27
+14.02%
|
-95.68
-40.22%
|
-68.24
|
| Net Income Common Stockholders |
|
-56.03
+33.08%
|
-83.74
+17.80%
|
-101.87
-49.28%
|
-68.24
|
| Diluted EPS |
|
-7.66
+30.36%
|
-11.00
+21.65%
|
-14.04
-39.01%
|
-10.10
|
| Basic EPS |
|
-7.66
+30.36%
|
-11.00
+21.65%
|
-14.04
-39.01%
|
-10.10
|
| Basic Average Shares |
|
7.32
+0.37%
|
7.29
+0.48%
|
7.26
+7.70%
|
6.74
|
| Diluted Average Shares |
|
7.32
+0.37%
|
7.29
+0.48%
|
7.26
+7.70%
|
6.74
|
| Diluted NI Availto Com Stockholders |
|
-56.03
+33.08%
|
-83.74
+17.80%
|
-101.87
-49.28%
|
-68.24
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
76.65
-47.02%
|
144.68
-34.60%
|
221.24
-26.15%
|
299.57
|
| Current Assets |
|
75.73
-44.92%
|
137.49
-33.56%
|
206.95
-27.57%
|
285.72
|
| Cash Cash Equivalents And Short Term Investments |
|
71.88
-45.65%
|
132.25
-34.33%
|
201.37
-27.19%
|
276.56
|
| Cash And Cash Equivalents |
|
71.88
+72.17%
|
41.75
+17.63%
|
35.49
-12.27%
|
40.46
|
| Cash Equivalents |
|
—
|
41.14
+16.38%
|
35.35
|
—
|
| Cash Financial |
|
—
|
0.61
+322.92%
|
0.14
|
—
|
| Other Short Term Investments |
|
0.00
-100.00%
|
90.50
-45.44%
|
165.88
-29.74%
|
236.10
|
| Receivables |
|
2.00
+112.90%
|
0.94
-66.46%
|
2.80
|
—
|
| Other Receivables |
|
1.81
+252.72%
|
0.51
-75.55%
|
2.10
|
—
|
| Accrued Interest Receivable |
|
0.18
-56.60%
|
0.42
-38.99%
|
0.69
|
—
|
| Prepaid Assets |
|
1.14
-71.24%
|
3.95
+56.28%
|
2.53
-72.38%
|
9.16
|
| Assets Held For Sale Current |
|
0.52
|
0.00
|
—
|
—
|
| Other Current Assets |
|
0.20
-43.02%
|
0.35
+39.84%
|
0.25
-72.72%
|
0.92
|
| Total Non Current Assets |
|
0.92
-87.28%
|
7.19
-49.64%
|
14.29
+3.17%
|
13.85
|
| Net PPE |
|
0.92
-80.85%
|
4.78
-45.01%
|
8.69
-34.03%
|
13.17
|
| Gross PPE |
|
4.20
-62.57%
|
11.22
-20.45%
|
14.11
-20.61%
|
17.77
|
| Accumulated Depreciation |
|
-3.29
+49.01%
|
-6.45
-18.91%
|
-5.42
-17.77%
|
-4.60
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.18
-96.85%
|
5.85
+0.10%
|
5.84
+25.22%
|
4.67
|
| Other Properties |
|
0.75
-60.29%
|
1.89
-60.53%
|
4.78
-50.95%
|
9.74
|
| Leases |
|
3.27
-6.31%
|
3.49
+0.00%
|
3.49
+3.62%
|
3.37
|
| Non Current Accounts Receivable |
|
—
|
1.74
|
—
|
—
|
| Non Current Prepaid Assets |
|
0.00
-100.00%
|
0.67
-87.66%
|
5.46
|
—
|
| Other Non Current Assets |
|
—
|
—
|
0.13
-80.12%
|
0.67
|
| Total Liabilities Net Minority Interest |
|
6.57
-76.32%
|
27.77
-17.52%
|
33.66
+13.37%
|
29.70
|
| Current Liabilities |
|
6.57
-67.66%
|
20.33
+14.57%
|
17.74
+61.35%
|
11.00
|
| Payables And Accrued Expenses |
|
4.18
-52.85%
|
8.87
-19.54%
|
11.02
+113.15%
|
5.17
|
| Payables |
|
0.51
-86.11%
|
3.65
-55.75%
|
8.25
+232.84%
|
2.48
|
| Accounts Payable |
|
0.51
-86.11%
|
3.65
-55.75%
|
8.25
+232.84%
|
2.48
|
| Current Accrued Expenses |
|
3.67
-29.58%
|
5.22
+88.21%
|
2.77
+2.97%
|
2.69
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.07
-97.57%
|
2.72
-26.75%
|
3.71
+13.74%
|
3.26
|
| Current Debt And Capital Lease Obligation |
|
2.33
-73.40%
|
8.74
+190.27%
|
3.01
+17.43%
|
2.56
|
| Current Debt |
|
—
|
5.22
|
—
|
—
|
| Other Current Borrowings |
|
—
|
5.22
|
—
|
—
|
| Current Capital Lease Obligation |
|
2.33
-34.03%
|
3.53
+17.07%
|
3.01
+17.43%
|
2.56
|
| Other Current Liabilities |
|
—
|
—
|
0.11
-60.00%
|
0.27
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
-100.00%
|
7.44
-53.29%
|
15.92
-14.86%
|
18.70
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
-100.00%
|
7.44
-53.29%
|
15.92
-14.86%
|
18.70
|
| Long Term Debt |
|
—
|
5.11
-49.24%
|
10.07
+2.39%
|
9.83
|
| Long Term Capital Lease Obligation |
|
0.00
-100.00%
|
2.33
-60.25%
|
5.85
-33.99%
|
8.87
|
| Stockholders Equity |
|
70.07
-40.07%
|
116.92
-37.67%
|
187.57
-30.50%
|
269.87
|
| Common Stock Equity |
|
70.07
-40.07%
|
116.92
-37.67%
|
187.57
-30.50%
|
269.87
|
| Capital Stock |
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
-89.71%
|
0.07
|
| Common Stock |
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
-89.71%
|
0.07
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
7.33
+0.38%
|
7.30
+0.35%
|
7.28
+6.26%
|
6.85
|
| Ordinary Shares Number |
|
7.33
+0.38%
|
7.30
+0.35%
|
7.28
+6.26%
|
6.85
|
| Additional Paid In Capital |
|
560.60
+1.64%
|
551.57
+2.44%
|
538.46
+3.62%
|
519.62
|
| Retained Earnings |
|
-490.53
-12.90%
|
-434.50
-23.87%
|
-350.76
-40.93%
|
-248.89
|
| Gains Losses Not Affecting Retained Earnings |
|
0.00
+100.00%
|
-0.16
-24.62%
|
-0.13
+85.92%
|
-0.92
|
| Other Equity Adjustments |
|
—
|
-0.16
-24.62%
|
-0.13
+85.92%
|
-0.92
|
| Total Equity Gross Minority Interest |
|
70.07
-40.07%
|
116.92
-37.67%
|
187.57
-30.50%
|
269.87
|
| Total Capitalization |
|
70.07
-42.58%
|
122.03
-38.26%
|
197.64
-29.34%
|
279.71
|
| Working Capital |
|
69.16
-40.97%
|
117.16
-38.08%
|
189.21
-31.13%
|
274.73
|
| Invested Capital |
|
70.07
-44.93%
|
127.24
-35.62%
|
197.64
-29.34%
|
279.71
|
| Total Debt |
|
2.33
-85.62%
|
16.18
-14.54%
|
18.93
-10.96%
|
21.26
|
| Capital Lease Obligations |
|
2.33
-60.25%
|
5.85
-33.98%
|
8.86
-22.45%
|
11.43
|
| Net Tangible Assets |
|
70.07
-40.07%
|
116.92
-37.67%
|
187.57
-30.50%
|
269.87
|
| Tangible Book Value |
|
70.07
-40.07%
|
116.92
-37.67%
|
187.57
-30.50%
|
269.87
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-51.78
+30.23%
|
-74.21
+9.10%
|
-81.64
-38.74%
|
-58.85
|
| Cash Flow From Continuing Operating Activities |
|
-51.78
+30.23%
|
-74.21
+9.10%
|
-81.64
-38.74%
|
-58.85
|
| Net Income From Continuing Operations |
|
-56.03
+33.08%
|
-83.74
+17.80%
|
-101.87
-49.28%
|
-68.24
|
| Depreciation Amortization Depletion |
|
0.90
-13.75%
|
1.04
-2.44%
|
1.07
+4.20%
|
1.02
|
| Depreciation And Amortization |
|
0.90
-13.75%
|
1.04
-2.44%
|
1.07
+4.20%
|
1.02
|
| Other Non Cash Items |
|
0.47
+74.53%
|
0.27
+12.18%
|
0.24
+6.25%
|
0.22
|
| Stock Based Compensation |
|
8.96
-31.11%
|
13.01
-28.26%
|
18.14
+29.49%
|
14.01
|
| Asset Impairment Charge |
|
0.91
-41.45%
|
1.55
-46.73%
|
2.91
|
0.00
|
| Operating Gains Losses |
|
0.43
|
—
|
—
|
0.01
|
| Net Foreign Currency Exchange Gain Loss |
|
0.28
|
0.00
|
0.00
|
—
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
0.01
|
| Change In Working Capital |
|
-5.40
-315.62%
|
-1.30
-127.62%
|
4.71
+205.54%
|
-4.46
|
| Change In Prepaid Assets |
|
1.91
+469.85%
|
0.34
-90.65%
|
3.58
+161.91%
|
-5.79
|
| Change In Payables And Accrued Expense |
|
-7.34
-133.25%
|
-3.15
-149.57%
|
6.35
+249.89%
|
1.81
|
| Change In Other Working Capital |
|
-2.39
-43.14%
|
-1.67
-450.83%
|
-0.30
-222.34%
|
-0.09
|
| Change In Other Current Assets |
|
2.42
-24.06%
|
3.18
+164.62%
|
-4.92
-1155.36%
|
-0.39
|
| Change In Other Current Liabilities |
|
—
|
—
|
—
|
-0.09
|
| Investing Cash Flow |
|
92.46
+14.96%
|
80.43
+5.76%
|
76.05
+183.21%
|
-91.39
|
| Cash Flow From Continuing Investing Activities |
|
92.46
+14.96%
|
80.43
+5.76%
|
76.05
+183.21%
|
-91.39
|
| Net PPE Purchase And Sale |
|
0.11
+489.66%
|
-0.03
+98.39%
|
-1.80
-14.39%
|
-1.58
|
| Purchase Of PPE |
|
-0.01
+72.41%
|
-0.03
+98.40%
|
-1.81
-14.70%
|
-1.58
|
| Sale Of PPE |
|
0.12
|
0.00
-100.00%
|
0.01
|
0.00
|
| Capital Expenditure |
|
-0.01
+72.41%
|
-0.03
+98.40%
|
-1.81
-14.70%
|
-1.58
|
| Net Investment Purchase And Sale |
|
92.35
+14.78%
|
80.46
+3.35%
|
77.85
+186.68%
|
-89.81
|
| Purchase Of Investment |
|
-42.63
+53.33%
|
-91.34
+49.37%
|
-180.40
+45.70%
|
-332.20
|
| Sale Of Investment |
|
134.98
-21.43%
|
171.79
-33.48%
|
258.25
+6.54%
|
242.39
|
| Financing Cash Flow |
|
-10.59
-10376.70%
|
0.10
-83.86%
|
0.64
-99.50%
|
127.86
|
| Cash Flow From Continuing Financing Activities |
|
-10.59
-10376.70%
|
0.10
-83.86%
|
0.64
-99.50%
|
127.86
|
| Net Issuance Payments Of Debt |
|
-10.65
|
0.00
|
0.00
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
0.00
|
0.00
|
| Repayment Of Debt |
|
-10.65
|
0.00
|
0.00
|
—
|
| Long Term Debt Issuance |
|
—
|
—
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
-10.65
|
0.00
|
0.00
|
—
|
| Net Long Term Debt Issuance |
|
-10.65
|
0.00
|
0.00
|
0.00
|
| Net Common Stock Issuance |
|
0.07
-36.89%
|
0.10
-83.86%
|
0.64
-99.50%
|
126.54
|
| Proceeds From Stock Option Exercised |
|
—
|
0.10
-83.86%
|
0.64
-51.63%
|
1.32
|
| Changes In Cash |
|
30.10
+376.36%
|
6.32
+227.37%
|
-4.96
+77.83%
|
-22.38
|
| Effect Of Exchange Rate Changes |
|
0.03
+144.44%
|
-0.06
-3050.00%
|
-0.00
+95.92%
|
-0.05
|
| Beginning Cash Position |
|
41.75
+17.63%
|
35.49
-12.27%
|
40.46
-35.66%
|
62.88
|
| End Cash Position |
|
71.88
+72.17%
|
41.75
+17.63%
|
35.49
-12.27%
|
40.46
|
| Free Cash Flow |
|
-51.78
+30.25%
|
-74.24
+11.04%
|
-83.45
-38.12%
|
-60.42
|
| Interest Paid Supplemental Data |
|
0.77
-42.62%
|
1.33
+1.52%
|
1.31
+35.15%
|
0.97
|
| Amortization Of Securities |
|
-2.00
+60.30%
|
-5.04
+26.16%
|
-6.83
-387.51%
|
-1.40
|
| Common Stock Issuance |
|
0.07
-36.89%
|
0.10
-83.86%
|
0.64
-99.50%
|
126.54
|
| Issuance Of Capital Stock |
|
0.07
-36.89%
|
0.10
-83.86%
|
0.64
-99.50%
|
126.54
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-03 View
- 8-K2026-03-30 View
- 10-K2026-03-27 View
- 8-K2026-03-12 View
- 10-Q2025-11-12 View
- 8-K2025-11-12 View
- 8-K2025-11-07 View
- 8-K2025-10-22 View
- 8-K2025-10-16 View
- 10-Q2025-08-13 View
- 8-K2025-08-13 View
- 42025-07-03 View
- 42025-07-03 View
- 42025-07-01 View
- 42025-06-23 View
- 42025-06-23 View
- 42025-06-23 View
- 42025-06-23 View
- 42025-06-23 View
- 42025-06-23 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|